ArticleAsian Pacific journal of cancer prevention : APJCP2025
In Silico Analysis of the Role of Estrogen Signaling in the Expression of Metabolic Genes in Breast Cancer.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEstrogen exerts a multifaceted influence on breast cancer, particularly through its association with estrogen receptor (ER) and progesterone receptor (PR), which serve as pivotal prognostic and therapeutic markers. While the differential expression of metabolic genes and their prognostic relevance in breast cancer have been extensively studied, limited research has examined their regulation by estrogen signaling. This study adopts a novel approach by investigating the effect of estrogen signaling on the expression of a broad spectrum of metabolic genes in breast cancer. METHODOLOGY: Microarray data from breast cancer studies were retrieved from the NCBI Gene Expression Omnibus (GEO). Differential expression profiles of ER+PR+ versus ER-PR- samples across seven datasets were analyzed using GEO2R. The 250 most significantly overexpressed and underexpressed genes were identified, and genes with metabolic functions were filtered. Promoter and upstream sequences (up to 1000 bp) of the most common transcript variants were obtained from the UCSC Genome Browser (Hg38 cell line). Estrogen receptor elements (EREs) and CpG islands were subsequently identified.
resultsThirty-three unique metabolic genes were identified based on differential expression profiles. Out of these, 18 genes were identified as having EREs in their upstream regions- CA12, CPA3, FBP1, STC2, NME5, DEGS2, ABAT, GAMT, and ARSG were upregulated, whereas B3GNT5, DPH2, PPARA, TNFRSF21, PHGDH, FOXL1, ME1, RNF145, and NUDT5 were downregulated. CpG islands closely corresponded to the EREs in PPARA, PHGDH, ME1, RNF145, NUDT5, CA12, STC2, ABAT, and GAMT. DISCUSSION: The identification of CA12, consistent with previous findings on its role in oncogenesis and estrogen regulation, highlights the therapeutic potential of targeting this pathway. Furthermore, the additional genes identified expand our understanding of metabolic alterations in response to estrogen signaling in breast cancer, thereby offering new avenues for mechanistic exploration and the development of potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.